Solid Tumor Targeting CAR-T Development Service through Thin-Film Nitinol (TFN) Micromesh

Q: How does TFN enhance CAR-T efficacy in solid tumors?

TFN creates a protected stimulatory niche via fibrin/CD3/CD28/CD137 functionalization, enabling localized T-cell expansion and sustained release to overcome TME suppression.

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs is pioneering the next generation of adoptive cell therapy, unlocking the potential of CAR-T in non-resectable solid tumors. Ineffective CAR-T cell trafficking and low persistence within the hostile tumor microenvironment (TME) remain major challenges in achieving optimal therapeutic outcomes. Our Solid Tumor Targeting CAR-T Development Service using Thin-Film Nitinol (TFN) Micromesh provides high-density, localized T-cell delivery and superior tumor clearance by leveraging precision-engineered, bioactive TFN implants that functionally support T-cell expansion in situ, enhancing infiltration and overall anti-tumor efficacy.

Introduction

The hostile tumor microenvironment (TME) presents formidable barriers to CAR-T cell trafficking, infiltration, and persistence in solid tumors, especially in unresectable lesions. Systemic infusion often results in low tumor accumulation, rapid T-cell exhaustion, and suboptimal anti-tumor activity. Thin-Film Nitinol (TFN) micromesh represents a breakthrough biomaterial-enabled strategy to overcome these limitations by establishing a localized, supportive niche for CAR-T cells directly at the tumor site.

Why Choose TFN Micromesh?

Material Properties: Thin-film Nitinol (NiTi) is superelastic, shape-memory, biocompatible, and ultra-thin, allowing implantable micromesh scaffolds for local cell delivery.

Structural Advantages: The porous mesh supports cell adhesion, local CAR-T expansion, and scattered tumor infiltration, improving penetration compared to systemic infusion.

Processability and Surface Functionalization: Micro-patterning, coatings, or chemical grafting control cell attachment, release, and immune compatibility, supporting short-term delivery and cell survival.

Programming CAR-T cells with bioactive materials for potentiated tumor therapy. (OA Literature) Fig.1 Bioactive material-engineered CAR-T cells for enhanced tumor therapy.¹

Creative Biolabs' CAR-T Development by Thin-Film Nitinol Micromesh Service

Creative Biolabs offers a comprehensive solution to overcome the primary challenge of solid tumor immunotherapy: delivery and survival. We enable the strategic application of high-potency CAR T cells directly at the tumor site via our advanced TFN platform. This platform uses Nitinol's unique biocompatibility and superelasticity, along with a customized fibrin/antibody coating (anti-CD3/CD28/CD137) to create an ex vivo bioreactor that rapidly expands and releases high-density, potent CAR-T cells directly at the tumor site. The strategic localization ensures a therapeutic effect far superior to conventional injection methods, enabling tumor clearance in models where standard approaches fail. The approach ensures maximal therapeutic density, superior proliferation, and long-term persistence where it matters most, leading to significantly enhanced tumor clearance compared to conventional systemic or local injection methods.

Discover How We Can Help - Request a Consultation.

Key Technical Elements

Manufacturing and Material Engineering
TFN Fabrication		Surface Treatment	Cell Attachment and Retention		Aseptic Handling and Cellular Assembly
Analysis	Key Readouts			Methods
In Vitro Analysis	Nickel ion release, cytotoxicity			Viability/proliferation assays
	Attachment efficiency, phenotype stability			Live-cell imaging, flow cytometry, metabolic assays
	Cell migration and killing in 3D tumor models			Tumor spheroid or tissue-slice co-culture, invasion depth analysis
	Cell retention under mechanical stress			Compression/deformation tests followed by cell quantification
In Vivo Analysis	Persistence at the implant site; migration patterns			Histology, tissue flow cytometry, reporter imaging
	Tumor control and survival benefit			Tumor volume monitoring, survival curves
	Inflammation, tissue response, cytokine levels			Organ pathology, serum cytokine profiling
	Fibrosis, foreign-body reaction, ion release over time			Histopathology, elemental analysis, and immunostaining

Work Process

Workflow of Thin-Film Nitinol Micromesh. (Creative Biolabs Original)

The final deliverables include a comprehensive TFN fabrication and functionalization report with detailed protocols and QC data, a CAR-T cell release and expansion data package with flow cytometry and migration assay results, and an in vivo efficacy and survival report with bioluminescence imaging, tumor cell density measurements, and statistical analysis.

Core Benefits

Precision-Engineered Delivery Platform: TFN micromeshes provide geometrically defined porosity for predictable cell loading and controlled release kinetics, enabling reproducible clinical-scale manufacturing.
Maximum Local Cell Density: TFN achieves higher CAR-T concentration at tumor sites while maintaining effector phenotype through anti-exhaustion functionalization.
Dual-Format Versatility: Configurable as 2D films for tumor wrapping or 3D stents for lumen patency, with bioactive stents reducing tumor stenosis.

FAQs

How does TFN enhance CAR-T efficacy in solid tumors?

TFN creates a protected stimulatory niche via fibrin/CD3/CD28/CD137 functionalization, enabling localized T-cell expansion and sustained release to overcome TME suppression.

What is the biocompatibility of Nitinol implants?

Nitinol is proven safe in permanent human implants. Ultra-thin TFN meshes show minimal inflammation, no systemic toxicity, and negligible fibrosis in long-term studies.

How does TFN compare to hydrogel/polymer scaffolds?

Unlike thick polymer scaffolds with random pores, TFN's thin precision geometry ensures optimal oxygen/nutrient diffusion and predictable cell distribution.

Partner with Us

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service through TFN Micromesh offers a validated, high-impact solution to the challenges of solid tumor therapy. By combining advanced biomaterials engineering with cutting-edge cell therapy functionalization, we deliver T-cell density, proliferation, and tumor clearance rates that far surpass conventional methods. Partner with us to transition your promising CAR-T candidates from the bench to therapeutic reality.

Reference

Huang, Guojun, et al. "Bioactive-Material-Programmed CAR-T Cell Living Drug for Augmented Immunotherapy against Tumors." Cell Reports Physical Science, 2024. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1016/j.xcrp.2024.102022

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.